Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

5.3%

1 terminated/withdrawn out of 19 trials

Success Rate

90.9%

+4.4% vs industry average

Late-Stage Pipeline

16%

3 trials in Phase 3/4

Results Transparency

40%

4 of 10 completed trials have results

Key Signals

3 recruiting4 with results

Enrollment Performance

Analytics

Phase 1
5(35.7%)
Phase 2
5(35.7%)
Phase 3
2(14.3%)
N/A
1(7.1%)
Phase 4
1(7.1%)
14Total
Phase 1(5)
Phase 2(5)
Phase 3(2)
N/A(1)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (19)

Showing 19 of 19 trials
NCT06572046Recruiting

STOP-HSP.Net: a Registry for Hereditary Spastic Paraplegia as an Integration Tool for Future Therapeutic Strategies

Role: collaborator

NCT03488394Phase 1Active Not Recruiting

Gene Therapy With Modified Autologous Hematopoietic Stem Cells for the Treatment of Patients With Mucopolysaccharidosis Type I, Hurler Variant

Role: collaborator

NCT03837483Phase 3Active Not Recruiting

A Clinical Study to Evaluate the Use of a Cryopreserved Formulation of OTL-103 in Subjects With Wiskott-Aldrich Syndrome

Role: lead

NCT03055247Phase 2Recruiting

Combination of Ibuprofen, G-CSF and Plerixafor as Stem Cells Mobilization Regimen in Patients Affected by X-CGD

Role: collaborator

NCT01515462Phase 1Completed

Gene Therapy for Wiskott-Aldrich Syndrome

Role: lead

NCT03814499Completed

Natural History Study in Subjects With Usher Syndrome

Role: lead

NCT04846335Phase 2Completed

Familiar Fatal Insomnia: Preventive Treatment With Doxycycline in Subject With Disease Risk

Role: collaborator

NCT03173521Phase 1Completed

Gene Therapy in Patients With Mucopolysaccharidosis Disease

Role: lead

NCT06448663Not ApplicableRecruiting

Targeting the Gut to Improve Seizure Control in CDKL5 Deficiency Disorder (CDD)

Role: collaborator

NCT03311074Phase 4Withdrawn

Retroviral Insertion Site Methodology Study

Role: lead

NCT00598481Phase 2Completed

ADA Gene Transfer Into Hematopoietic Stem/Progenitor Cells for the Treatment of ADA-SCID

Role: lead

NCT04959890Unknown

Methodology Study of Retroviral Insertion Site Analysis in Strimvelis Gene Therapy

Role: lead

NCT03478670Enrolling By Invitation

Strimvelis Registry Study to Follow-up Patients With Adenosine Deaminase Severe Combined Immunodeficiency (ADA-SCID)

Role: lead

NCT03232203Completed

Evaluating the Effectiveness of STRIMVELIS Risk Minimization Measures (RMMs)

Role: lead

NCT03734263Phase 2Completed

Use of Phenylbutyrate Therapy for Patients With Pyruvate Dehydrogenase Complex Deficiency.

Role: lead

NCT02453477Phase 1Unknown

Gene Therapy for Transfusion Dependent Beta-thalassemia

Role: collaborator

NCT01812551Phase 3Completed

Treatment of Low Bone Density in Cystic Fibrosis.

Role: collaborator

NCT01133860Phase 2Completed

Efficacy of Eltrombopag to Improve Thrombocytopenia of MYH9-related Disease

Role: collaborator

NCT00599781Phase 1Completed

Gene Therapy for ADA-SCID

Role: collaborator

All 19 trials loaded